Free Trial

iTeos Therapeutics (ITOS) News Today

iTeos Therapeutics logo
$7.47 +0.12 (+1.63%)
(As of 12/24/2024 04:01 PM ET)
iTeos Therapeutics, Inc. stock logo
iTeos Therapeutics (NASDAQ:ITOS) Price Target Lowered to $19.00 at Wells Fargo & Company
Wells Fargo & Company cut their price objective on shares of iTeos Therapeutics from $31.00 to $19.00 and set an "overweight" rating for the company in a research report on Thursday.
iTeos Therapeutics, Inc. stock logo
HC Wainwright Reiterates "Buy" Rating for iTeos Therapeutics (NASDAQ:ITOS)
HC Wainwright reissued a "buy" rating and issued a $21.00 target price on shares of iTeos Therapeutics in a research note on Friday.
iTeos Therapeutics, Inc. stock logo
RA Capital Management L.P. Sells 332,548 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)
RA Capital Management L.P. lessened its holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 9.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,184,711 shares of the company's stock after selling 332,
iTeos Therapeutics, Inc. stock logo
Readystate Asset Management LP Has $1.73 Million Stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS)
Readystate Asset Management LP raised its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 97.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 169,819 shares of the company's stock after acquiring an ad
iTeos Therapeutics, Inc. stock logo
Vestal Point Capital LP Has $10.47 Million Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)
Vestal Point Capital LP trimmed its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 41.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,025,000 shares of the company's stock after selling 725,00
iTeos Therapeutics, Inc. stock logo
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Bought by Algert Global LLC
Algert Global LLC grew its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 92.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 256,139 shares of the company's stock after buying a
iTeos to Participate in Upcoming Investor Conferences
iTeos Therapeutics, Inc. stock logo
iTeos Therapeutics' (ITOS) "Buy" Rating Reiterated at HC Wainwright
HC Wainwright reissued a "buy" rating and issued a $46.00 price objective on shares of iTeos Therapeutics in a research report on Friday.
iTeos Therapeutics, Inc. stock logo
Wedbush Predicts Stronger Earnings for iTeos Therapeutics
iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Equities researchers at Wedbush boosted their FY2024 earnings per share (EPS) estimates for iTeos Therapeutics in a research note issued on Tuesday, November 12th. Wedbush analyst D. Nierengarten now anticipates that the company will post ear
iTeos Therapeutics Reports Q3 2024 Financial Results
iTeos Therapeutics, Inc. stock logo
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Stock Position Decreased by AQR Capital Management LLC
AQR Capital Management LLC trimmed its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 66.0% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 29,298 shares of the company's stock after selling 56,870 shares
iTeos Therapeutics, Inc. stock logo
Millennium Management LLC Decreases Stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS)
Millennium Management LLC lessened its stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 72.7% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 241,305 shares of the company's stock after selling 641,676 shares
iTeos Therapeutics, Inc. stock logo
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Short Interest Update
iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) was the target of a significant increase in short interest in September. As of September 30th, there was short interest totalling 4,820,000 shares, an increase of 92.0% from the September 15th total of 2,510,000 shares. Based on an average daily volume of 518,700 shares, the short-interest ratio is presently 9.3 days. Currently, 17.2% of the company's stock are short sold.
iTeos Therapeutics, Inc. stock logo
Dimensional Fund Advisors LP Grows Stock Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)
Dimensional Fund Advisors LP increased its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 14.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 908,329 shares of the comp
iTeos Therapeutics, Inc. stock logo
156,894 Shares in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Bought by Clearline Capital LP
Clearline Capital LP bought a new position in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 156,894 shares of the company's stock, valued at approxim
iTeos Therapeutics, Inc. stock logo
Renaissance Technologies LLC Sells 157,700 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)
Renaissance Technologies LLC trimmed its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 22.0% in the second quarter, according to its most recent filing with the SEC. The fund owned 559,600 shares of the company's stock after selling 157,700 shares during the period. Renaissanc
iTeos Therapeutics, Inc. stock logo
Wedbush Weighs in on iTeos Therapeutics, Inc.'s FY2027 Earnings (NASDAQ:ITOS)
iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Wedbush lifted their FY2027 earnings per share (EPS) estimates for shares of iTeos Therapeutics in a note issued to investors on Sunday, September 15th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($
iTeos Therapeutics (ITOS) Receives a Buy from Piper Sandler
iTeos Therapeutics, Inc. stock logo
iTeos Therapeutics' (ITOS) Buy Rating Reiterated at HC Wainwright
HC Wainwright restated a "buy" rating and issued a $46.00 target price on shares of iTeos Therapeutics in a report on Monday.
iTeos Therapeutics, Inc. stock logo
iTeos Therapeutics (NASDAQ:ITOS) Sees Large Volume Increase
iTeos Therapeutics (NASDAQ:ITOS) Sees Unusually-High Trading Volume
iTeos Therapeutics, Inc. stock logo
iTeos Therapeutics (NASDAQ:ITOS) Shares Up 8.2%
iTeos Therapeutics (NASDAQ:ITOS) Trading 8.2% Higher
iTeos Therapeutics, Inc. stock logo
Candriam S.C.A. Invests $7.56 Million in iTeos Therapeutics, Inc. (NASDAQ:ITOS)
Candriam S.C.A. bought a new stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 509,303 shares of the company's stock, valued at approximately $7,558,0
iTeos to Participate in Upcoming Investor Conferences
iTeos Therapeutics, Inc. stock logo
iTeos Therapeutics (NASDAQ:ITOS) Shares Gap Up to $15.89
iTeos Therapeutics (NASDAQ:ITOS) Shares Gap Up to $15.89
ITOS Sep 2024 13.000 put (ITOS240920P00013000)
ITOS Sep 2024 18.000 put (ITOS240920P00018000)
Get iTeos Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter.

Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)

I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.

Click here to see the details because I believe a lot of people will get rich.

ITOS Media Mentions By Week

ITOS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ITOS
News Sentiment

-0.12

0.58

Average
Medical
News Sentiment

ITOS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ITOS Articles
This Week

2

2

ITOS Articles
Average Week

Get iTeos Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ITOS) was last updated on 12/25/2024 by MarketBeat.com Staff
From Our Partners